AKT1 and central nervous system cancer: Several AKT inhibitors are currently in phase III clinical trials,[27] while the ERK inhibitor TIC10 has received FDA approval for the treatment of H3K27M‐mutated glioma.[28] The discovery that PTPN14 inhibits the phosphorylation and activation of AKT and ERK highlights the potential of PTPN14 as a target for cancer therapy.